Blood-based molecular biomarkers for Alzheimer's disease
- PMID: 30922367
- PMCID: PMC6437931
- DOI: 10.1186/s13041-019-0448-1
Blood-based molecular biomarkers for Alzheimer's disease
Abstract
A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer's disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current health system to find and diagnose patients with early AD pathology. This may be related in part to the limited capacity of the current health systems to select those people likely to have AD pathology in order to confirm the diagnosis with available cerebrospinal fluid and imaging biomarkers at memory clinics. In the current narrative review, we summarize the literature on candidate blood tests for AD that could be implemented in primary care settings and used for the effective identification of individuals at increased risk of AD pathology, who could be referred for potential inclusion in clinical trials or future approved treatments following additional testing. We give an updated account of blood-based candidate biomarkers and biomarker panels for AD-related brain changes. Our analysis centres on biomarker candidates that have been replicated in more than one study and discusses the need of further studies to achieve the goal of a primary care-based screening algorithm for AD.
Keywords: Alzheimer’s disease; Amyloid; Biomarkers; Blood; Plasma; Serum; Tau.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx and is one of the founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. SB reports no disclosures.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Similar articles
-
Biomarkers for Alzheimer's disease: current status and prospects for the future.J Intern Med. 2018 Dec;284(6):643-663. doi: 10.1111/joim.12816. Epub 2018 Aug 19. J Intern Med. 2018. PMID: 30051512 Review.
-
The early diagnosis of Alzheimer's disease: Blood-based panel biomarker discovery by proteomics and metabolomics.CNS Neurosci Ther. 2024 Nov;30(11):e70060. doi: 10.1111/cns.70060. CNS Neurosci Ther. 2024. PMID: 39572036 Free PMC article. Review.
-
Exosome-encapsulated microRNAs as promising biomarkers for Alzheimer's disease.Rev Neurosci. 2019 Dec 18;31(1):77-87. doi: 10.1515/revneuro-2019-0001. Rev Neurosci. 2019. PMID: 31318699 Review.
-
The Past and the Future of Alzheimer's Disease Fluid Biomarkers.J Alzheimers Dis. 2018;62(3):1125-1140. doi: 10.3233/JAD-170773. J Alzheimers Dis. 2018. PMID: 29562534 Free PMC article. Review.
-
Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.J Alzheimers Dis. 2017;60(4):1641-1652. doi: 10.3233/JAD-170426. J Alzheimers Dis. 2017. PMID: 29125490
Cited by
-
Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample.Neurology. 2023 Feb 21;100(8):e874-e883. doi: 10.1212/WNL.0000000000201289. Epub 2022 Nov 29. Neurology. 2023. PMID: 36446595 Free PMC article.
-
Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies.Alzheimers Dement. 2024 Apr;20(4):2485-2496. doi: 10.1002/alz.13653. Epub 2024 Feb 8. Alzheimers Dement. 2024. PMID: 38329197 Free PMC article.
-
AMD Genomics: Non-Coding RNAs as Biomarkers and Therapeutic _targets.J Clin Med. 2022 Mar 9;11(6):1484. doi: 10.3390/jcm11061484. J Clin Med. 2022. PMID: 35329812 Free PMC article. Review.
-
MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders.Front Pharmacol. 2020 Jan 17;10:1555. doi: 10.3389/fphar.2019.01555. eCollection 2019. Front Pharmacol. 2020. PMID: 32009959 Free PMC article. Review.
-
Screening of Crucial Differentially-Methylated/Expressed Genes for Alzheimer's Disease.Am J Alzheimers Dis Other Demen. 2022 Jan-Dec;37:15333175221116220. doi: 10.1177/15333175221116220. Am J Alzheimers Dis Other Demen. 2022. PMID: 35848539 Free PMC article.
References
-
- Calderon-Garciduenas AL, Duyckaerts C. Alzheimer disease. Handb Clin Neurol. 2017;145:325–337. - PubMed
-
- Cohen AD, Landau SM, Snitz BE, Klunk WE, Blennow K, Zetterberg H. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Mol Cell Neurosci. 2018. - PubMed
-
- Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–684. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical